Deciphera Pharmaceuticals, Inc. (DCPH)
| Market Cap | 2.85B |
| Revenue (ttm) | 22.60M |
| Net Income (ttm) | -270.97M |
| Shares Out | 56.39M |
| EPS (ttm) | -4.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $50.07 |
| Previous Close | $51.17 |
| Change ($) | -1.10 |
| Change (%) | -2.15% |
| Day's Open | 50.87 |
| Day's Range | 49.66 - 51.75 |
| Day's Volume | 485,345 |
| 52-Week Range | 33.63 - 69.39 |
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. M...
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the eff...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced data presentations from clinical studies of QINLOCK, the Company's switch-control tyrosine kinas...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual...
Deciphera (DCPH) reports a narrower-than-expected loss and sales beat estimates in the third quarter of 2020.
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2020 Results - Earnings Call Transcript
PETACH TIKVA, Israel and WALTHAM, Mass., Nov. 6, 2020 /PRNewswire/ -- Medison Pharma, a leading international commercial partner for highly innovative therapies, today announced an exclusive d...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results and provided a business update for the third quarter ended September 30, 2020. ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020. In co...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q2 2020 Results - Earnings Call Transcript
Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q2 2020 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 10.45% and 249.26%, respectively, for the quarter ended June 2020.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the Australian Therapeutic Goods Administration (TGA) has approved QINLOCK™ (ripretinib), a ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibit...
Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.
After 17 years of clinical work, Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) finally has a marketable product.
Approval of its cancer-fighting drug could make all the difference.
The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.
Deciphera stock popped Monday after the biotech gained FDA approval for a stomach cancer treatment. The drug, known by brand name Qinlock, treats gastrointestinal stromal tumors.
Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q1 2020 Results - Earnings Call Transcript
Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q1 2020 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.25% and -97.52%, respectively, for the quarter ended March 2020.
Deciphera (DCPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Blueprint Medicines Corp (NASDAQ: BPMC) shares were taking a beating Tuesday after the company announced a negative late-stage readout for its lead asset avapritinib in third- or fourth-line g...
Deciphera Pharmaceuticals (DCPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Deciphera Pharmaceuticals: Updates To Thesis, Expecting A Rebound Ahead Of August PDUFA
Investors are concerned that an important regulatory deadline for the development-stage drug developer will be delayed because of the coronavirus pandemic.
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q4 2019 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -15.93% and -100.00%, respectively, for the quarter ended December 2019.
The company announced a public stock offering as it prepares for a potential regulatory approval in 2020.
The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.
The solid end of the year performance meant shares nearly tripled in 2019.
They have what deep-pocketed pharmaceutical giants want.
Deciphera: Analysis Of The Market Potential Of Ripretinib
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q3 2019 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -7.56% and -100.00%, respectively, for the quarter ended September 2019.
Deciphera Pharmaceuticals, Inc. (DCPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Deciphera announced positive data from the phase 3 study using ripretinib to treat patients with fourth-line and fifth-line plus gastrointestinal stromal tumors.
About DCPH
Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I tri... [Read more...]
| Industry Biotechnology | IPO Date Sep 28, 2017 |
| CEO Steven Hoerter | Employees 255 |
| Stock Exchange NASDAQ | Ticker Symbol DCPH |
Analyst Forecasts
According to 10 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is 76.42, which is an increase of 52.63% from the latest price.